上海医药：替格瑞洛片获美国FDA批准文号

Core Insights - Shanghai Pharmaceuticals (601607) announced on November 6 that its subsidiary, Changzhou Pharmaceutical Factory, received final approval from the U.S. Food and Drug Administration (FDA) for the abbreviated new drug application of Ticagrelor tablets, which are intended for patients with acute coronary syndrome to reduce the incidence of thrombotic cardiovascular events [1] - Additionally, the subsidiary, Shanghai Pharmaceuticals Zhongxi, received a drug registration certificate from the National Medical Products Administration for the production of Tocilizumab sustained-release tablets, which are used to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [1] Group 1 - The FDA approval for Ticagrelor tablets marks a significant milestone for Shanghai Pharmaceuticals in the cardiovascular drug market [1] - The approval indicates the company's commitment to expanding its product offerings in critical therapeutic areas [1] - The registration of Tocilizumab sustained-release tablets further enhances the company's portfolio in the treatment of autoimmune diseases [1]